A nationally recognized, comprehensive program dedicated to the conduct of basic, translational, clinical, and population-based research in advancing the understanding, diagnosis, and treatment of cancer and hematological disorders
Our mission is to train the next generation of cancer researchers and clinical leaders by providing clinical inpatient and outpatient practice education along with research training under the supervision of world-renowned specialists
Internationally recognized for our leadership in the prevention, detection, diagnosis, and treatment of cancer. We are committed to meeting the highest standards of cancer care and providing the most advanced treatments.
Dr. Taofeek Owonikoko
Taofeek Owonikoko, MD, PhD joined the the UPMC Hillman Cancer Center and Department of Medicine as the Chief of the Division of Hematology/Oncology in July 2021. He is the Associate Director for Translational Research and Co-Leader of the Cancer Therapeutics Program at Hillman. Dr. Owonikoko holds the Stanley M. Marks – OHA Endowed Chair in Hematology/Oncology Leadership. He will is a key member of the senior leadership team at Hillman, helping to oversee our translational research, development of novel therapeutics, and expediting efforts to expand our clinical trials across the entire Hillman network. As division chief, he works with the leaders in the department of medicine to identify, cultivate and mentor the next generation of clinical and research leaders in oncology by creating a robust pipeline of training and mentoring programs.
Dr. Owonikoko is a physician-scientist, board-certified in Medical Oncology, Hematology and Internal Medicine with a clinical focus on treating patients with lung cancer. His research interests are in pre-clinical biomarker discovery in lung cancer and other solid tumor types, and translation of promising laboratory findings into clinical trials in collaboration with academic and industry partners. He has received extramural grant funding in support of his laboratory and translational research from the National Institutes of Health, Department of Defense and private foundations.
PACCM and Hematology/Oncology faculty collaborate to identify link between telomere mutations and melonama
In a recent Science paper, Drs. Jonathan Alder, John Kirkwood and others describe TPP1 mutations leading to telomere lengthening and the promotion of melanoma cells.
Division of Hematology Oncology residents, trainees and faculty are strongly represented at this year's annual meeting of the American Society of Hematology (ASH) held in New Orleans, Louisiana, December 10-13, 2022, presenting their translational, clinical and basic...
Highlighted Publications A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease. In this Phase 1 single-center, open-label study of the novel red-cell pyruvate kinase (PKR) activator mitapivat (AG-348) for the...
Division of Hematology/Oncology
UPMC Cancer Pavilion
5150 Centre Avenue, 5th floor
Pittsburgh, PA 15232
412-648-6575 | Email Us
UPMC Hillman Cancer Center
5115 Centre Avenue
Pittsburgh, PA 15232